Location of Repository

Menopause and cardiovascular, metabolic and bone parameters

By Suzy Honisett

Abstract

After menopause women experience an increased risk of developing cardiovascular disease, diabetes and osteoporosis. The work described in this thesis investigates the effects of exercise, hormonal therapy (HT) and rosiglitazone on cardiovascular risk variables, glucose and insulin levels and bone turnover markers. It was hypothesised that these interventions would independentiy improve parameters measured, whilst combined treatment would provide further benefit

Topics: 1103 Clinical Sciences, 1102 Cardiorespiratory Medicine and Haematology, School of Biomedical and Health Sciences, Menopause, Hormone therapy, exercise, women, Osteoporosis, cardiovascular disease, diabetes
Year: 2002
OAI identifier: oai:eprints.vu.edu.au:15605
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://vuir.vu.edu.au/15605/1/... (external link)
  • http://vuir.vu.edu.au/15605/ (external link)
  • Suggested articles

    Preview

    Citations

    1. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal ceUs and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.
    2. 17 betaestradiol stimulates prostacyclin, but not endothehn-l, production in human vascular endotiiehal ceUs.
    3. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an ATla antagonist and tioghtazone.
    4. (2001). A complex role for the progesterone receptor in fhe response to vascular injury.
    5. A controUed trial of the effect of calcium supplementation on bone density in postmenopausal women.
    6. A link between hypertension obesity and glucose intolerance.
    7. A novel, nongenomic action of estrogen on the cardiovascular system.
    8. A prospective stady of matarity-onset diabetes meUitas and risk of coronary heart disease and stroke in women.
    9. A prostaglandin J2 metaboHte binds peroxisome proHferator-activated receptor gamma and promotes adipocyte differentiation.
    10. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians.
    11. Acute effect of 17 beta-estradiol on rabbit coronary artery contractUe responses to endothelin-1. ^w/P^j-z'o/1992;263(1
    12. Acute effects of glucose on reactivity of cerebral microcirculation: role of activation of protein kinase C.
    13. Acute effects of transdermal estrogen in postmenopausal women with coronary artery disease. Using a chnicaUy relevant estrogen dose and concurrent antianginal therapy.
    14. Acute vascular effects of estrogen in postmenopausal women.
    15. Additive effects of weightbearing exercise and estrogen on bone mineral density in older women.
    16. Advanced glycation end products, oxidant stress and vascular lesions.
    17. Adverse influence of systemic vascular stiffening on cardiac dysfunction and adaptation to acute coronary occlusion.
    18. Age and menopause-related changes in indices of bone tuxnovet.
    19. (1998). Agerelated deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement th.er.apy. Arterioscler Thromb Vase Biol
    20. Aging is associated with endothehal dysfunction in healthy men years before the age-related decHne in women.
    21. Alteration of plasma endothehn-l by exercise at intensities lower and higher than ventilatory threshold.
    22. (1991). Alterations in endothehum-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats.
    23. Annual skeletal balance and metaboHc bone marker changes in healthy early postmenopausal women: results of a prospective stady.
    24. Aortic distensibihty and left ventricular structure and function in isolated systoHc hypertension.
    25. Aortic distensibUity in patients with isolated hypercholesterolaemia, coronary artery disease, or cardiac transplant.
    26. Aromatase inhibition alters vascular reactivity and arterial compHance in men: a possible vascular role for endogenous sex hormones in males.
    27. (1995). Artenal compHance may influence baroreflex function in athletes and hypertensives.
    28. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Stady Investigators.
    29. Behavioral stress responses in premenopausal and postmenopausal women and tiie effects of estrogen.
    30. Bidirectional regulation of osteoclast function by nittic oxide synthaseisoforms.
    31. Blood pressure lowering by pioghtazone. Evidence for a direct vascular effect.
    32. Bone density in premenopausal women: effects of age, dietary Hitake, physical activity, smokuig, and birth-control pUls.
    33. Bone endothehal ceUs as estrogen targets.
    34. Brisk walking does not stop bone loss in postmenopausal women.
    35. (1991). Can vigorous exercise play a role in osteoporosis prevention? A review.
    36. Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids.
    37. Cardiac and glycemic benefits of troghtazone treatment in NIDDM. The TrogHtazone Study Group.
    38. Cardiovascular impHcations of estrogen replacement therapy. Obstet Gynecol 1990;75(4 Suppl): 18S-25S; discussion 31S-35S.
    39. Cardiovascular mortahty and noncontraceptive use of estrogen in women: results from the Lipid Research CHnics Program FoUow-up Study.
    40. Cardiovascular protection by oestrogen—a calcium antagonist effect?
    41. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controUed study with nomegestrol acetate and estradiol.
    42. Changes in physical fitness and aU-cause mortahty. A prospective study of healtiiy and unhealthy men.
    43. (1990). Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoHne, two new markers of bone coUagen turnover. / Bone Miner Res
    44. Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblastic ceUs and effect of steroid hormones on ceU proHferation.
    45. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    46. CHnical review 27: Effects of hormonal replacement on Hpids and Hpoproteins in postmenopausal women.
    47. Cholesterol and mortahty. 30 years of foUowup from the Framingham study.
    48. Clinical use of biochemical markers of bone remodehng in osteoporosis.
    49. Comparative morphomettic changes in rat cortical bone foUowing ovariectomy and/or immobilization.
    50. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum Hpids and Hpoproteins.
    51. Control of vascular ceU proHferation and migration by PPAR-gamma: a new approach to the macrovascular comphcations of diabetes.
    52. (2002). Controversial issues in cHmacteric medicine. Cardiovascular disease and hormone replacement therapy.International Menopause Society Expert Workshop.
    53. Coronary heart disease in patients with diabetes.
    54. Coronary-heart-disease risk and impaired glucose tolerance. The WhitehaU study.
    55. Cytokines and bone loss in a 5-year longitudinal study—hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study.
    56. Cytokines and estrogen in bone: anti-osteoporotic effects.
    57. cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.
    58. Decreased effect of insuHn to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.
    59. Diabetes aboHshes the vascular protective effects of estrogen in female rats.
    60. Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen.
    61. (1998). Disorders of the reproductive tract.
    62. Effect of age on calcium absorption.
    63. Effect of aging on response to exercise training in humans: skeletal muscle GLUT-4 and insuHn sensitivity.
    64. Effect of changing levels of physical activity on blood-pressure and haemodynamics in essential hypertension.
    65. Effect of estradiol on the sympathoadrenal response to mental stress in normal men.
    66. Effect of exercise hitensity on bone density, strength, and calcium turnover in older women.
    67. Effect of exercise training in 60- to 69-year-old persons with essential hypertension.
    68. Effect of intraarterial insuHn on tissue cholesterol and fatty acids in aUoxan-diabetic dogs.
    69. Effect of metformin and rosigHtazone combination therapy in patients with type 2 diabetes meUitus: a randomized controUed tnal.
    70. (2001). Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomised controlled trial.
    71. Effect of reduced training and training cessation on insuHn action and muscle
    72. Effect of starting age of physical activity on bone mass in the dominant arm of tennis and squash players.
    73. Effects of 17-beta-estradiol and progesterone.
    74. (1999). Effects of acute admimstration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women. AbnJ Cardiol
    75. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China.
    76. Effects of endurance exercise and hormone replacement therapy on serum Hpids in older women [see comments]. 7^4^
    77. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women.
    78. Effects of exercise and estrogen therapy on Hpid profiles of postmenopausal women.
    79. Effects of exercise and lack of exercise on insuHn sensitivity and responsiveness.
    80. Effects of exercise conditioning on physiologic precursors of coronary heart disease.
    81. Effects of exercise training on the chemical composition of plasma LDL.
    82. Effects of Hfetime voUeybaU exercise on bone mineral densities in lumbar spine, calcaneus and tibia for pre-, peri- and postmenopausal women.
    83. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controUed tnal.
    84. Effects of hypertension and its reversal on canine arterial waU properties.
    85. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metaboHsm in ^ostTaeno^rnxs^woruen.
    86. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity.
    87. Effects of TrogHtazone (CS-045) on insuHn secretion in isolated rat pancreatic islets and HIT ceUs: an insuHnotropic mechanism distinct from ghbenclamide.
    88. Effects of troghtazone: a new hypoglycemic agent in patients with NIDDM poorly controUed by diet therapy.
    89. Effects of waUdng and other exercise programs upon blood pressure in normal subjects.
    90. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controUed trial.
    91. EndotheHum in the control of vascular tone and growth: role of local mediators and mechanical forces.
    92. EndotheHum regulates skeletal muscle microcirculation by a blood flow velocity-sensing mechanism.
    93. Endothehumindependent relaxation of rabbit coronary artery by 17 beta- oestradiol in vitro.
    94. Endurance exercise training improves body composition and plasma insulin responses in 70- to 79-year-old men and women.
    95. Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women.
    96. Estimation of total arterial compHance: an improved method and evaluation of current metiiods.
    97. Estradiol therapy combined with progesterone and endothehumdependent vasodilation in postmenopausal women.
    98. Estrogen and coronary heart disease in women.
    99. Estrogen and progesterone inhibit vascular smooth muscle proHferation.
    100. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma hpids in postmenopausal women with noninsuHndependent diabetes meUitus.
    101. Estrogen-mduced production of a peroxisome proHferator-activated receptor (PPAR) ligand in a PPARgamma-expressing hssue.
    102. Exercise increases muscle GLUT-4 levels and insuHn action in subjects with impaired glucose tolerance.
    103. Exercise training increases GLUT-4 protein concentration in previously sedentary middle-aged men.
    104. Exercise training lowers resting renal but not cardiac sympathetic activity in humans.
    105. Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation.
    106. Expression and function of PPARgamma in rat and human vascular smooth muscle ceUs.
    107. Fetal pancreatic islets express functional leptin receptors and leptin stimulates proHferation of fetal islet ceUs.
    108. Flow activates an endothehal potassium channel to release an endogenous nitrovasodUator.
    109. Flow restriction of one carotid artery in juvenUe rats inhibits growtii of arterial diameter.
    110. Flowdependent coronary artery dilatation in humans.
    111. (1991). Four weeks of cycle training increases basal production of nitric oxide from the forearm.
    112. Functional estrogen receptors in a human preosteoclastic ceU Hne.
    113. Gender considerations in hypertension patiiophysiology and treatment.
    114. Glucose tolerance and blood pressure in two population samples: their relation to diabetes meUitus and hypertension.
    115. Helsinki Heart Study: primaryprevention trial with gemfibrozU in middle-aged men with dysHpidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    116. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.
    117. Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors.
    118. (2001). Hormone replacement therapy and cardiovasular disease: A statement for healthcare professionals from the Amercian Heart Association. Circulation
    119. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: the northern cahfornia kaiser permanente diabetes registry.
    120. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women.
    121. (1991). Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum Hpoproteins and glucose tolerance during 24 montii foUow up.
    122. Hormone therapy to prevent disease and prolong Hfe in postmenopausal ^omen.
    123. HRT and exercise: effects on bone density, muscle strength and Hpid metaboHsm. A placebo controUed 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.
    124. Hyperinsvilinemia produces both sympathetic neural activation and vasodilation in normal humans.
    125. (1999). Hypertension and insuHn resistance: role of peroxisome proHferator-activated receptor gamma. Clin Exp Pharmacol Physiol
    126. Hypertension m diabetes mellitus.
    127. Impaired contraction and endothehum-dependent relaxation in isolated resistance vessels from patients with insuHn-dependent diabetes meUitas.
    128. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: role of polyol pathway.
    129. Impaired endothehum-dependent and independent vasodUation in patients with type 2 (non-insuhn-dependent) diabetes meUitas.
    130. Impaired endothehumdependent relaxation in isolated resistance arteries of spontaneously diabetic rats.
    131. Impaired vascular reactivity in insulindependent diabetes melhtus is related to disease duration and low density Hpoprotein cholesterol levels.
    132. (1994). Impairment of endothehum-dependent relaxation in aortae from spontaneously diabetic rats.
    133. Improvement in glucose tolerance and insuHn resistance in obese subjects treated with troghtazone.
    134. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status./
    135. In vivo arterial compHance in man.
    136. Increased osteoclast development after estrogen loss: mediation by interleukin-6.
    137. Increased plasma plasminogen activator inhibitor 1 levels. A possible Hnk between insuHn resistance and atherothrombosis.
    138. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insuHn-dependent diabetes.
    139. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomi2ed monkeys. Lack of an effect of added progesterone.
    140. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta aUografts.
    141. (1996). Inhibition of oxidation of low density Hpoprotein by troghtazone. Atherosclerosis
    142. Inhibition of peroxisome proHferator signaHng pathways by thyroid hormone receptor. Competitive binding to the response element.
    143. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis.
    144. InsuHn binding to monocytes and insuHn action in human obesity, starvation, and refeeding.
    145. InsuHn receptors during the menstrual cycle in normal women.
    146. InsuHn resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy.
    147. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: impHcations for preventing coronary heart disease during the prediabetic state.
    148. Is borderUne fasting hyperglycemia a risk factor for cardiovascular death?
    149. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study.
    150. Isoflavones from red clover improve systemic arterial compHance but not plasma Hpids in menopausal women.
    151. K Effects of hormone replacement therapy on Hpoprotein(a) and Hpids in postmenopausal women.
    152. K Effects of menopause on aortic root function in hypertensive women.
    153. Leptm in postmenopausal women: influence of hormone therapy, insuHn, and fat distribution.
    154. Lifetime leisure exercise and osteoporosis. The Rancho Bernardo study.
    155. Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insviUn-sensitizmg agent pioghtazone.
    156. Long-term effects of varying intensities and formats of physical activity on participation rates, fitaess, and Hpoproteins in men and women aged 50 to 65 years.
    157. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an Hicreased bone mass after delayed onset of oestrogen treatment.
    158. Lower prevalence of diabetes in female former coUege athletes compared with nonathletes.
    159. Macrophages in human atheroma contain PPARgamma: differentiation- dependent peroxisomal proHferatoractivated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro.
    160. Measurement of leg arterial compHance of normal subjects and diabetics using impedance plethysmography.
    161. Mechanism of impaired responses of cerebral arterioles during diabetes meUitas.
    162. Mechanisms of action of steroid hotmones.
    163. Mechanisms of insuHn resistance in human obesity: evidence for receptor and postreceptor defects.
    164. Mechanisms of vasorelaxation induced by troghtazone, a novel antidiabetic drug, in the porcine coronary artery.
    165. Medroxyprogesterone mterferes with ovarian steroid protection against coronary vasospasm.
    166. (1999). Menopausal symptoms m Austrahan women.
    167. MetaboHc basis of obesity and noninsulin-dependent diabetes meUitus. Diabetes Metab Rev 1988;4(8):
    168. MetaboHc effects of troghtazone on fructose-induced insulin resistance in the rat.
    169. Metformin improves peripheral but not hepatic insuHn action in obese patients with type II daahetes.
    170. Moderate exercise does not enhance the positive effect of estrogen on bone mineral density in postmenopausal women.
    171. Modification of forearm resistance vessels by exercise training in young men.
    172. Natural menopause and cardiovascular disease risk factors. The Poland and US Collaborative Study on Cardiovascular Disease Epidemiology.
    173. Nitric oxide and hone.
    174. Nitric oxide synthase expression in bone ceUs.
    175. Non-invasive detection of endothehal dysfunction in chUdren and adults at risk of atherosclerosis.
    176. Non-invasive measurements of arterial structare and function: repeatabihty, interrelationships and trial sample size.
    177. Non-invasive test of microvascular endothehal function in normal and hypertensive pregnancies.
    178. Novel plasma membrane action of estrogen and antiestrogens revealed by their regulation of a large conductance chloride channel.
    179. Obesity and insuHn resistance in humans: a dose-response study.
    180. Oestrogen relaxes human epicardial coronary arteries through non- endothehum-dependent mechanisms.
    181. Osteoporosis and the replacement of ceU populations of the marrow by adipose tissue. A quantitative stady of 84 Uiac bone biopsies.
    182. Oviarectomy in rmce increases osteocalcin levels in the serum and enhances osteoblast progenitor formation in the bone marrow (Abstract). Bone Mineral 1994;2S:
    183. Past and recent physical activity and risk of hip fracture.
    184. Peak trabecular vertebral density: a comparison of adolescent and adult females.
    185. Peroxisome proHferator-activated receptor-gamma activation by thiazoHdinediones induces adipogenesis in bone marrow stromal ceUs.
    186. Peroxisome proHferatoractivated receptor gamma activators inhibit gene expression and migration in human vascular smootii muscle ceUs.
    187. (1991). Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain.
    188. Physical exercise and hypertension. New insights and cHnical impHcations.
    189. physical fitoess, and bone density.
    190. Physical training and baroreceptor control of sympathetic nerve activity in humans.
    191. Pioghtazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats.
    192. Pioghtazone increases insuHn sensitivity, reduces blood glucose, insulin, and Hpid levels, and lowers blood pressure, in obese, insuHn- resistant rhesus monkeys.
    193. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density Hpoprotein cholesterol level: a meta-analysis of population-based prospective stxxdiies.
    194. Position stand: physical activity, physical fitaess, and hypertension. Med Sci Sports Exerc 1993;25: i-x.
    195. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium.
    196. PPAR gamma-hgands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle ceUs.
    197. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study.
    198. Preliminary in situ identification of estrogen target ceUs in bone.
    199. Progesterone and modulation of endothehum-dependent responses in canine coronary arteries.
    200. Progesterone induces endothehum-independent relaxation of rabbit coronary artery in vitro.
    201. (1991). Progesterone inhibits arterial smootii muscle ceU proHferation. Nat Med
    202. Progesterone receptors in the human heart and great vessels.
    203. Randomised controUed trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures [see comments].
    204. Reduced mortahty associated with long-term postmenopausal estrogen therapy.
    205. Reduction of insuHn resistance in obese and/or diabetic animals by 5- [4-(lmethylcyclohexyHnethoxy)benzyl]-thiazoHdine-2,4-dione (ADD-3878, U-63,287, cigHtazone), a new antidiabetic agent.
    206. Regional aortic compHance stadied by magnetic resonance imaging: the effects of age, training, and coronary artery disease.
    207. Regulation of hemopoiesis by bone marrow stromal ceUs and their products.
    208. Relation between coronary artery disease, aortic stiffness, and left ventricular structure in a population sample.
    209. Relation of abdominal obesity to hyperinsuhnemia and high blood pressure in men.
    210. Relationship between obesity and maximal insuHn-stimulated glucose uptake in vivo and in vitro in Pima Indians.
    211. Relationship of plasma insvUin levels to the incidence of myocardial infarction and coronary heart disease mortahty in a middle-aged population.
    212. Resistance to metaboHc actions of insulin and its role in hypertension.
    213. Response of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM.
    214. (1991). Risk factors for diabetes in three Pacific populations.
    215. Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion.
    216. Roles of PPARs in health and disease.
    217. RosigHtazone in combination with a statin: effect on Hpid profile in patients with type 2 diabetes melhtus. American Endocrinology Conference,
    218. RosigHtazone monotherapy is effective in patients with type 2 diabetes.
    219. (2001). RosigHtazone: effects on insixHn resistance syndrome. American Endocrinology Society,
    220. Sex hormones and coronary disease: a review of the cHnical studies.
    221. Short-term oestrogen replacement therapy improves insuHn resistance, Hpids and fibrinolysis in postmenopausal women with NIDDM.
    222. Steroid receptors in human osteoblast-Hke ceUs.
    223. Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis.
    224. Studies on the stoichiometry of estrogen oxidation catalyzed by purified prostaglandin-H-synthase holoenzyme.
    225. (1997). Superoxide dismutase partiaUy restores impaired dUatation of the basUar artery durmg diabetes meUitas. Brain Res
    226. (1999). Systemic arterial compHance is reduced in young patients with IDDM.
    227. Systemic endothehal dysfunction is related to the extent and severity of coronary artery disease.
    228. The effect of 17 beta oestradiol on human endothehal ceU nitric oxide production (abstract).
    229. The effect of hormonal replacement therapy on the vascular reactivity and endothehal function of healthy individuals and individuals with type 2 diabetes.
    230. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controUed study of four levels of activity.
    231. The effects of long-term low intensity aerobic training and detraining on serum Hpid and Hpoprotein concentrations in elderly men and women.
    232. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.
    233. The independent effects of exercise and estrogen on Hpids and Hpoproteins in postmenopausal women.
    234. The menopause and hormone replacement therapy.
    235. (2002). The Nobel Foundation.
    236. The protective effects of estrogen on the cardiovascular system.
    237. The risk of acute myocardial infarction after oestrogen and oestrogenprogestogen replacement
    238. The role of aerobic training in the regulation of vascular tone. Nutr Metab Cardiovascular Dis 1998;8:
    239. The role of exercise in the treatment of hypertension in obesity.
    240. The role of nitric oxide and other endothehum-derived vasoactive substances in vascular disease.
    241. (1994). The route of administration influences the effect of estrogen on insuHn sensitivity in postmenopausal women. Fertil Steril
    242. The vascular protective effects of estrogen.
    243. ThiazoHdinediones Repress ob Gene Expression in Rodents Via Activation of Perisome ProHferator-activated Receptor gamma.
    244. ThiazoHdinediones—tools for the research of metaboHc syndrome X.
    245. Time-course of the antihypertensive and autonomic effects of regular endurance exercise in human subjects.
    246. TrogHtazone inhibits vascular smooth muscle ceU growth and intimal hyperplasia.
    247. (2001). TrogHtazone upregulates nitric oxide synthesis in vascular smooth muscle ceUs. Hypertensio 1999;33: 943-8. healthhsite
    248. TrogHtazone, an insuHn sensitiser, increases forearm blood flow in humans.
    249. Two antiatherogenic effects of progesterone on human macrophages; inhibition of cholesteryl ester synthesis and block of its enhancement by glucocorticoids.
    250. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women.
    251. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women.
    252. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women.
    253. VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioghtazone.
    254. Why is diabetes meUitus a strong risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.